Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy

Table 4

Phase III clinical studies with lonidamine in lung cancer.

Patients accrued	Treatment	Main findings	Observations	References
184	LND versus mit + vds versus LND + mit + vds	ORR (%); 3.4% versus 22.4% versus 25.9%	1-year OS rate; mit + vds 20%; mit + vds + LND 32%	[55]
158	cis + epi + vds versus cis + epi + vds + LDN	ORR (%); 24 versus 43	Median TTP; 5 versus 8 m.; Median OS; 7.6 versus 11 m.	[56]
151	MACC versus MACC + LND	ORR (%); 7 versus 13	Median PFS; 17 versus 20 weeks; Median OS; 27 versus 30 weeks	[57]
126	LND versus vds versus LND + vds versus BSC	ORR (%); LND 3.3; LDN + vds 6	Elderly patients; Median OS all pts 24.2 weeks; No differences among regimens	[58]
310	LND + RT versus pla + RT	More local control in LND + RT arm ()	Median PFS; 7.6 versus 6.5 months,; Median OS; 13 versus 10.8 months	[59]

mit: mitomycin-C; vds: vindesine; MACC; methotrexate-doxorubicin-cyclophosphamide-CCNU; BSC: best supportive care; ORR: overall response rate; PFS: progression-free survival; OS: overall survival; TTP: time to progression.